查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631384

子宮癌症診斷檢驗的全球市場:產業分析，規模，佔有率，成長，趨勢，預測(2025年～2032年)

Uterine Cancer Diagnostic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 241 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

2025年，全球子宮癌診斷檢測市場規模預計為35.471億美元，2025-2032年預測期間複合年增長率為9.60%，到2032年將達到67億美元。萬。

全球子宮癌診斷測試市場包括旨在檢測子宮內膜癌和子宮內膜癌（包括子宮肉瘤）的超音波檢查、活檢方法和血液檢查等診斷解決方案。子宮內膜癌盛行率的增加、診斷技術的進步以及老年人口的增加推動了市場的成長。醫療保健基礎設施、意識計劃和政府措施的改善也支持市場擴張。

有幾個因素正在推動全球子宮癌診斷測試市場的成長。子宮內膜癌的盛行率不斷上升，特別是在停經後和肥胖女性中，強調了早期檢測方法的必要性。經陰道超音波掃描和 CA125 腫瘤標記血液檢測等診斷技術的進步提高了準確性和可靠性，刺激了市場推廣。增加醫療保健支出，尤其是在新興經濟體，支持診斷解決方案的開發和可近性。此外，政府促進婦女健康和癌症篩檢以及提高早期診斷意識的措施也對市場成長做出了重大貢獻。

由於技術進步和醫療保健服務範圍的擴大，子宮癌診斷測試市場提供了巨大的成長機會。微創診斷工具的開發提高了患者的依從性並擴大了市場滲透率。由於醫療基礎設施投資增加以及政府對癌症篩檢的支持舉措，新興國家的潛力尚未開發。診斷解決方案提供者和醫療保健組織之間的合作可以加速創新並擴大服務提供。此外，對個人化醫療和精準診斷的日益關注為市場擴張提供了新的途徑。

本報告提供全球子宮癌症診斷檢驗市場相關調查，提供癌症各類型，診斷檢驗各類型，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 市場簡介

第3章 子宮癌症診斷檢驗市場觀點

第4章 全球子宮癌症診斷檢驗市場- 主要調查內容

第5章 北美的子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第6章 南美的子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第7章 歐洲的子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第8章 中國以外亞太地區的子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第9章 中國的子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第10章 中東·非洲的子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第11章 預測要素:相關性及影響

第12章 競爭情形

  • 競爭儀表板
  • 企業簡介(詳細內容- 概要，財務，策略，最近的趨勢)
  • 主要人物
    • Abbott
    • Roche Holdings AG
    • Siemens AG
    • Danaher
    • BioMerieux SA

第13章 全球子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)，各地區

第14章 全球子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)，癌症各類型

第15章 全球子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)，診斷檢驗各類型

第16章 全球子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)，各終端用戶

第17章 全球子宮癌症診斷檢驗市場分析(2019年～2024年)及預測(2025年～2032年)

第18章 所使用的假設和縮寫

第19章 調查手法

簡介目錄
Product Code: PMRREP17005

Persistence Market Research has recently released a comprehensive report on the global Uterine Cancer Diagnostic Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Uterine Cancer Diagnostic Testing Market Size (2025E): US$ 3,547.10 Mn
  • Projected Market Value (2032F): US$ 6,738.90 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.60%

Uterine Cancer Diagnostic Testing Market - Report Scope:

The global uterine cancer diagnostic testing market comprises diagnostic solutions such as ultrasound scanning, biopsy procedures, and blood tests aimed at detecting uterine cancer, which includes endometrial carcinoma and uterine sarcoma. The market growth is driven by the increasing prevalence of uterine cancer, advancements in diagnostic technologies, and the rising geriatric population. Improved healthcare infrastructure, awareness programs, and government initiatives also support market expansion.

Market Drivers:

Several factors are propelling the growth of the global uterine cancer diagnostic testing market. The rising prevalence of uterine cancer, particularly among post-menopausal and obese women, underscores the demand for early detection methods. Advances in diagnostic techniques, such as transvaginal ultrasound scanning and CA125 tumor marker blood tests, have improved accuracy and reliability, fueling market adoption. Increasing healthcare expenditure, especially in emerging economies, supports the development and accessibility of diagnostic solutions. Furthermore, government initiatives promoting women's health and cancer screenings, combined with rising awareness about early diagnosis, contribute significantly to market growth.

Market Restraints:

Despite the promising growth trajectory, the uterine cancer diagnostic testing market faces several challenges. High costs associated with advanced diagnostic procedures and limited healthcare infrastructure in certain regions can hinder market penetration. Awareness about uterine cancer diagnosis remains low in developing countries, impacting timely detection and treatment. The complexity and invasiveness of certain diagnostic procedures, such as dilation and curettage, may deter patients, particularly in regions with cultural and social barriers to medical intervention.

Market Opportunities:

The uterine cancer diagnostic testing market offers significant growth opportunities driven by technological advancements and expanding healthcare access. Development of minimally invasive diagnostic tools enhances patient compliance and broadens market adoption. Emerging economies present untapped potential due to increasing investments in healthcare infrastructure and government-backed initiatives for cancer screenings. Partnerships between diagnostic solution providers and healthcare organizations can accelerate innovation and expand service delivery. Additionally, the growing focus on personalized medicine and precision diagnostics provides new avenues for market expansion.

Key Questions Answered in the Report:

1. What are the primary factors driving the global growth of the uterine cancer diagnostic testing market?

2. Which diagnostic solutions are gaining the highest adoption across different regions?

3. How are advancements in diagnostic technologies shaping the competitive landscape of the uterine cancer diagnostic testing market?

4. Who are the key players in the uterine cancer diagnostic testing market, and what strategies are they employing to maintain their market positions?

5. What are the emerging trends and future outlooks for the global uterine cancer diagnostic testing market?

Competitive Intelligence and Business Strategy:

Leading companies in the global uterine cancer diagnostic testing market, such as Siemens Healthineers, Hologic, and GE Healthcare, are focusing on technological innovations and expanding their product portfolios to gain a competitive edge. These companies are leveraging collaborations with healthcare providers and research institutions to accelerate the development of advanced diagnostic solutions. Investments in AI-based imaging and non-invasive diagnostic technologies further support market growth. Additionally, companies are emphasizing affordability and accessibility to cater to diverse patient demographics, particularly in emerging economies.

Key Companies Profiled:

  • Abbott
  • Roche Holdings AG
  • Siemens AG
  • Danaher
  • BioMerieux SA
  • Others

Uterine Cancer Diagnostic Testing Market Segmentation:

By Cancer Type:

  • Endometrial Carcinoma
  • Uterine Sarcoma

By Diagnostic Test Type:

  • Ultrasound Scanning
  • Biopsy Procedures
  • Blood Tests

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Specialized Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Europe
  • Latin America
  • South East Asia & Pacific
  • Middle East & Africa (MEA)
  • China
  • Japan

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Uterine Cancer Diagnostic Testing Market View Point

  • 3.1. Macro-Economic Factors
  • 3.2. Market Drivers and Restraints
  • 3.3. Opportunity Analysis
  • 3.4. Global Key trends
  • 3.5. Reimbursement Scenario

4. Global Uterine Cancer Diagnostic Testing Market - Key Inclusions

  • 4.1. Regional Average Pricing Analysis
  • 4.2. Parent Market Assessment
  • 4.3. Epidemiology

5. North America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 5.1. Introduction
  • 5.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 5.2.1. U.S.
    • 5.2.2. Canada
  • 5.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 5.3.1. U.S.
    • 5.3.2. Canada
  • 5.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 5.4.1. Uterine Sarcoma
    • 5.4.2. Endometrial Carcinomas
  • 5.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 5.5.1. Uterine Sarcoma
    • 5.5.2. Endometrial Carcinomas
  • 5.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 5.6.1. Ultrasound Scanning
      • 5.6.1.1. Abdominal Ultrasound
      • 5.6.1.2. Transvaginal Ultrasound
    • 5.6.2. Biopsy
      • 5.6.2.1. Endometrial Biopsy
      • 5.6.2.2. Hysteroscopy
      • 5.6.2.3. Dilation and curettage
    • 5.6.3. Blood tests
      • 5.6.3.1. Complete blood Count
      • 5.6.3.2. CA-125 blood test
  • 5.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 5.7.1. Ultrasound Scanning
      • 5.7.1.1. Abdominal Ultrasound
      • 5.7.1.2. Transvaginal Ultrasound
    • 5.7.2. Biopsy
      • 5.7.2.1. Endometrial Biopsy
      • 5.7.2.2. Hysteroscopy
      • 5.7.2.3. Dilation and curettage
    • 5.7.3. Blood tests
      • 5.7.3.1. Complete blood Count
      • 5.7.3.2. CA-125 blood test
  • 5.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 5.8.1. Hospitals
    • 5.8.2. Ambulatory Surgical Centers
    • 5.8.3. Cancer Research Centers
    • 5.8.4. Specialized Clinics
    • 5.8.5. Diagnostic Laboratories
    • 5.8.6. Others
  • 5.9. Market Size Analysis 2025 - 2032, By End User
    • 5.9.1. Hospitals
    • 5.9.2. Ambulatory Surgical Centers
    • 5.9.3. Cancer Research Centers
    • 5.9.4. Specialized Clinics
    • 5.9.5. Diagnostic Laboratories
    • 5.9.6. Others
  • 5.10. Drivers and Restraints: Impact Analysis
  • 5.11. Market Attractiveness Analysis
    • 5.11.1. By Cancer Type
    • 5.11.2. By Test Type
    • 5.11.3. By End user
    • 5.11.4. By Country

6. Latin America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 6.1. Introduction
  • 6.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 6.2.1. Brazil
    • 6.2.2. Mexico
    • 6.2.3. Rest of Latin America
  • 6.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Rest of Latin America
  • 6.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 6.4.1. Uterine Sarcoma
    • 6.4.2. Endometrial Carcinomas
  • 6.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 6.5.1. Uterine Sarcoma
    • 6.5.2. Endometrial Carcinomas
  • 6.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 6.6.1. Ultrasound Scanning
      • 6.6.1.1. Abdominal Ultrasound
      • 6.6.1.2. Transvaginal Ultrasound
    • 6.6.2. Biopsy
      • 6.6.2.1. Endometrial Biopsy
      • 6.6.2.2. Hysteroscopy
      • 6.6.2.3. Dilation and curettage
    • 6.6.3. Blood tests
      • 6.6.3.1. Complete blood Count
      • 6.6.3.2. CA-125 blood test
  • 6.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 6.7.1. Ultrasound Scanning
      • 6.7.1.1. Abdominal Ultrasound
      • 6.7.1.2. Transvaginal Ultrasound
    • 6.7.2. Biopsy
      • 6.7.2.1. Endometrial Biopsy
      • 6.7.2.2. Hysteroscopy
      • 6.7.2.3. Dilation and curettage
    • 6.7.3. Blood tests
      • 6.7.3.1. Complete blood Count
      • 6.7.3.2. CA-125 blood test
  • 6.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 6.8.1. Hospitals
    • 6.8.2. Ambulatory Surgical Centers
    • 6.8.3. Cancer Research Centers
    • 6.8.4. Specialized Clinics
    • 6.8.5. Diagnostic Laboratories
    • 6.8.6. Others
  • 6.9. Market Size Analysis 2025 - 2032, By End User
    • 6.9.1. Hospitals
    • 6.9.2. Ambulatory Surgical Centers
    • 6.9.3. Cancer Research Centers
    • 6.9.4. Specialized Clinics
    • 6.9.5. Diagnostic Laboratories
    • 6.9.6. Others
  • 6.10. Drivers and Restraints: Impact Analysis
  • 6.11. Market Attractiveness Analysis
    • 6.11.1. By Cancer Type
    • 6.11.2. By Test Type
    • 6.11.3. By End user
    • 6.11.4. By Country

7. Europe Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 7.2.1. Germany
    • 7.2.2. U.K.
    • 7.2.3. France
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Poland
    • 7.2.7. Russia
    • 7.2.8. Rest of Europe
  • 7.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Poland
    • 7.3.7. Russia
    • 7.3.8. Rest of Europe
  • 7.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 7.4.1. Uterine Sarcoma
    • 7.4.2. Endometrial Carcinomas
  • 7.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 7.5.1. Uterine Sarcoma
    • 7.5.2. Endometrial Carcinomas
  • 7.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 7.6.1. Ultrasound Scanning
      • 7.6.1.1. Abdominal Ultrasound
      • 7.6.1.2. Transvaginal Ultrasound
    • 7.6.2. Biopsy
      • 7.6.2.1. Endometrial Biopsy
      • 7.6.2.2. Hysteroscopy
      • 7.6.2.3. Dilation and curettage
    • 7.6.3. Blood tests
      • 7.6.3.1. Complete blood Count
      • 7.6.3.2. CA-125 blood test
  • 7.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 7.7.1. Ultrasound Scanning
      • 7.7.1.1. Abdominal Ultrasound
      • 7.7.1.2. Transvaginal Ultrasound
    • 7.7.2. Biopsy
      • 7.7.2.1. Endometrial Biopsy
      • 7.7.2.2. Hysteroscopy
      • 7.7.2.3. Dilation and curettage
    • 7.7.3. Blood tests
      • 7.7.3.1. Complete blood Count
      • 7.7.3.2. CA-125 blood test
  • 7.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 7.8.1. Hospitals
    • 7.8.2. Ambulatory Surgical Centers
    • 7.8.3. Cancer Research Centers
    • 7.8.4. Specialized Clinics
    • 7.8.5. Diagnostic Laboratories
    • 7.8.6. Others
  • 7.9. Market Size Analysis 2025 - 2032, By End User
    • 7.9.1. Hospitals
    • 7.9.2. Ambulatory Surgical Centers
    • 7.9.3. Cancer Research Centers
    • 7.9.4. Specialized Clinics
    • 7.9.5. Diagnostic Laboratories
    • 7.9.6. Others
  • 7.10. Drivers and Restraints: Impact Analysis
  • 7.11. Market Attractiveness Analysis
    • 7.11.1. By Cancer Type
    • 7.11.2. By Test Type
    • 7.11.3. By End user
    • 7.11.4. By Country

8. Asia Pacific Excluding China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 8.1. Introduction
  • 8.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. Australia and New Zealand
    • 8.2.5. Rest of APAC
  • 8.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. India
    • 8.3.3. Japan
    • 8.3.4. Australia and New Zealand
    • 8.3.5. Rest of APAC
  • 8.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 8.4.1. Uterine Sarcoma
    • 8.4.2. Endometrial Carcinomas
  • 8.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 8.5.1. Uterine Sarcoma
    • 8.5.2. Endometrial Carcinomas
  • 8.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 8.6.1. Ultrasound Scanning
      • 8.6.1.1. Abdominal Ultrasound
      • 8.6.1.2. Transvaginal Ultrasound
    • 8.6.2. Biopsy
      • 8.6.2.1. Endometrial Biopsy
      • 8.6.2.2. Hysteroscopy
      • 8.6.2.3. Dilation and curettage
    • 8.6.3. Blood tests
      • 8.6.3.1. Complete blood Count
      • 8.6.3.2. CA-125 blood test
  • 8.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 8.7.1. Ultrasound Scanning
      • 8.7.1.1. Abdominal Ultrasound
      • 8.7.1.2. Transvaginal Ultrasound
    • 8.7.2. Biopsy
      • 8.7.2.1. Endometrial Biopsy
      • 8.7.2.2. Hysteroscopy
      • 8.7.2.3. Dilation and curettage
    • 8.7.3. Blood tests
      • 8.7.3.1. Complete blood Count
      • 8.7.3.2. CA-125 blood test
  • 8.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 8.8.1. Hospitals
    • 8.8.2. Ambulatory Surgical Centers
    • 8.8.3. Cancer Research Centers
    • 8.8.4. Specialized Clinics
    • 8.8.5. Diagnostic Laboratories
    • 8.8.6. Others
  • 8.9. Market Size Analysis 2025 - 2032, By End User
    • 8.9.1. Hospitals
    • 8.9.2. Ambulatory Surgical Centers
    • 8.9.3. Cancer Research Centers
    • 8.9.4. Specialized Clinics
    • 8.9.5. Diagnostic Laboratories
    • 8.9.6. Others
  • 8.10. Drivers and Restraints: Impact Analysis
  • 8.11. Market Attractiveness Analysis
    • 8.11.1. By Cancer Type
    • 8.11.2. By Test Type
    • 8.11.3. By End user
    • 8.11.4. By Country

9. China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 9.2.1. Uterine Sarcoma
    • 9.2.2. Endometrial Carcinomas
  • 9.3. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 9.3.1. Uterine Sarcoma
    • 9.3.2. Endometrial Carcinomas
  • 9.4. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 9.4.1. Ultrasound Scanning
      • 9.4.1.1. Abdominal Ultrasound
      • 9.4.1.2. Transvaginal Ultrasound
    • 9.4.2. Biopsy
      • 9.4.2.1. Endometrial Biopsy
      • 9.4.2.2. Hysteroscopy
      • 9.4.2.3. Dilation and curettage
    • 9.4.3. Blood tests
      • 9.4.3.1. Complete blood Count
      • 9.4.3.2. CA-125 blood test
  • 9.5. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 9.5.1. Ultrasound Scanning
      • 9.5.1.1. Abdominal Ultrasound
      • 9.5.1.2. Transvaginal Ultrasound
    • 9.5.2. Biopsy
      • 9.5.2.1. Endometrial Biopsy
      • 9.5.2.2. Hysteroscopy
      • 9.5.2.3. Dilation and curettage
    • 9.5.3. Blood tests
      • 9.5.3.1. Complete blood Count
      • 9.5.3.2. CA-125 blood test
  • 9.6. Historical Market Size Analysis 2019 - 2024, By End User
    • 9.6.1. Hospitals
    • 9.6.2. Ambulatory Surgical Centers
    • 9.6.3. Cancer Research Centers
    • 9.6.4. Specialized Clinics
    • 9.6.5. Diagnostic Laboratories
    • 9.6.6. Others
  • 9.7. Market Size Analysis 2025 - 2032, By End User
    • 9.7.1. Hospitals
    • 9.7.2. Ambulatory Surgical Centers
    • 9.7.3. Cancer Research Centers
    • 9.7.4. Specialized Clinics
    • 9.7.5. Diagnostic Laboratories
    • 9.7.6. Others
  • 9.8. Drivers and Restraints: Impact Analysis
  • 9.9. Market Attractiveness Analysis
    • 9.9.1. By Cancer Type
    • 9.9.2. By Test Type
    • 9.9.3. By End user
    • 9.9.4. By Country

10. Middle East and Africa (MEA) Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 10.2.1. South Africa
    • 10.2.2. Saudi Arabia
    • 10.2.3. Rest of MEA
  • 10.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 10.3.1. South Africa
    • 10.3.2. Saudi Arabia
    • 10.3.3. Rest of MEA
  • 10.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 10.4.1. Uterine Sarcoma
    • 10.4.2. Endometrial Carcinomas
  • 10.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 10.5.1. Uterine Sarcoma
    • 10.5.2. Endometrial Carcinomas
  • 10.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 10.6.1. Ultrasound Scanning
      • 10.6.1.1. Abdominal Ultrasound
      • 10.6.1.2. Transvaginal Ultrasound
    • 10.6.2. Biopsy
      • 10.6.2.1. Endometrial Biopsy
      • 10.6.2.2. Hysteroscopy
      • 10.6.2.3. Dilation and curettage
    • 10.6.3. Blood tests
      • 10.6.3.1. Complete blood Count
      • 10.6.3.2. CA-125 blood test
  • 10.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 10.7.1. Ultrasound Scanning
      • 10.7.1.1. Abdominal Ultrasound
      • 10.7.1.2. Transvaginal Ultrasound
    • 10.7.2. Biopsy
      • 10.7.2.1. Endometrial Biopsy
      • 10.7.2.2. Hysteroscopy
      • 10.7.2.3. Dilation and curettage
    • 10.7.3. Blood tests
      • 10.7.3.1. Complete blood Count
      • 10.7.3.2. CA-125 blood test
  • 10.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 10.8.1. Hospitals
    • 10.8.2. Ambulatory Surgical Centers
    • 10.8.3. Cancer Research Centers
    • 10.8.4. Specialized Clinics
    • 10.8.5. Diagnostic Laboratories
    • 10.8.6. Others
  • 10.9. Market Size Analysis 2025 - 2032, By End User
    • 10.9.1. Hospitals
    • 10.9.2. Ambulatory Surgical Centers
    • 10.9.3. Cancer Research Centers
    • 10.9.4. Specialized Clinics
    • 10.9.5. Diagnostic Laboratories
    • 10.9.6. Others
  • 10.10. Drivers and Restraints: Impact Analysis
  • 10.11. Market Attractiveness Analysis
    • 10.11.1. By Cancer Type
    • 10.11.2. By Test Type
    • 10.11.3. By End user
    • 10.11.4. By Country

11. Forecast Factors: Relevance and Impact

12. Competition Landscape

  • 12.1. Competition Dashboard
  • 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3. Key Players
    • 12.3.1. Abbott
    • 12.3.2. Roche Holdings AG
    • 12.3.3. Siemens AG
    • 12.3.4. Danaher
    • 12.3.5. BioMerieux SA

13. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

  • 13.1. Introduction
    • 13.1.1. Basis Point Share (BPS) Analysis by Region
    • 13.1.2. Y-o-Y Growth Projections by Region
  • 13.2. Historical Market Size Analysis 2019 - 2024, By Region
    • 13.2.1. North America
    • 13.2.2. Latin America
    • 13.2.3. Europe
    • 13.2.4. Asia Pacific Excluding China
    • 13.2.5. China
    • 13.2.6. Middle East and Africa (MEA)
  • 13.3. Market Size Analysis 2025 - 2032, By Region
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. Asia Pacific Excluding China
    • 13.3.5. China
    • 13.3.6. Middle East and Africa (MEA)
  • 13.4. Market Attractiveness Analysis by Region

14. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Cancer Type

  • 14.1. Introduction
    • 14.1.1. Basis Point Share (BPS) Analysis by Product Type
    • 14.1.2. Y-o-Y Growth Projections by Product Type
  • 14.2. Historical Market Size Analysis 2019 - 2024, By Cancer Type
    • 14.2.1. Uterine Sarcoma
    • 14.2.2. Endometrial Carcinomas
  • 14.3. Market Size Analysis 2025 - 2032, By Cancer Type
    • 14.3.1. Uterine Sarcoma
    • 14.3.2. Endometrial Carcinomas
  • 14.4. Market Attractiveness Analysis by Cancer Type

15. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Diagnostic Test Type

  • 15.1. Introduction
    • 15.1.1. Basis Point Share (BPS) Analysis by Test Type
    • 15.1.2. Y-o-Y Growth Projections by Test Type
  • 15.2. Historical Market Size Analysis 2019 - 2024, By Test Type
    • 15.2.1. Ultrasound Scanning
      • 15.2.1.1. Abdominal Ultrasound
      • 15.2.1.2. Transvaginal Ultrasound
    • 15.2.2. Biopsy
      • 15.2.2.1. Endometrial Biopsy
      • 15.2.2.2. Hysteroscopy
      • 15.2.2.3. Dilation and curettage
    • 15.2.3. Blood tests
      • 15.2.3.1. Complete blood Count
      • 15.2.3.2. CA-125 blood test
  • 15.3. Market Size Analysis 2025 - 2032, By Test Type
    • 15.3.1. Ultrasound Scanning
      • 15.3.1.1. Abdominal Ultrasound
      • 15.3.1.2. Transvaginal Ultrasound
    • 15.3.2. Biopsy
      • 15.3.2.1. Endometrial Biopsy
      • 15.3.2.2. Hysteroscopy
      • 15.3.2.3. Dilation and curettage
    • 15.3.3. Blood tests
      • 15.3.3.1. Complete blood Count
      • 15.3.3.2. CA-125 blood test
  • 15.4. Market Attractiveness Analysis by Test Type

16. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By End User

  • 16.1. Introduction
    • 16.1.1. Basis Point Share (BPS) Analysis by End User
    • 16.1.2. Y-o-Y Growth Projections by End User
  • 16.2. Historical Market Size Analysis 2019 - 2024, By End User
    • 16.2.1. Hospitals
    • 16.2.2. Ambulatory Surgical Centers
    • 16.2.3. Cancer Research Centers
    • 16.2.4. Specialized Clinics
    • 16.2.5. Diagnostic Laboratories
    • 16.2.6. Others
  • 16.3. Market Size Analysis 2025 - 2032, By End User
    • 16.3.1. Hospitals
    • 16.3.2. Ambulatory Surgical Centers
    • 16.3.3. Cancer Research Centers
    • 16.3.4. Specialized Clinics
    • 16.3.5. Diagnostic Laboratories
    • 16.3.6. Others
  • 16.4. Market Attractiveness Analysis by End User

17. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 17.1. Market Size and Y-o-Y Growth
  • 17.2. Absolute $ Opportunity

18. Assumptions and Acronyms Used

A glossary of assumption and acronyms used in the report

19. Research Methodology